The global Suppositories Market, valued at US$1.56 billion in 2024 stood at US$1.63 billion in 2025 and is projected to ...

Foundation Wealth Partners Inc. (“Foundation Wealth Partners” or “Foundation Wealth”) is proud to announce the promotion of Michael Lynn, ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and special ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

The US Court of Appeals for the Federal Circuit affirmed (on its second review) a district court’s ruling upholding the validity of patent claims related to a long-acting injectable dosing regimen, ...

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver ...

Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to Teva Pharmaceuticals in recognition of its outstanding commitment to ...

Anti-ICE riots forced temporary closures of HUD offices in Los Angeles, San Francisco and New York as Secretary Turner refutes Democrats' earlier claims about permanent shutdowns.

In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved populations worldwide via customized, localized models conducted with ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Teva Pharmaceuticals' credit rating upgraded to BB+ by Fitch, reflecting debt reduction and positive growth outlook.